The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia
Introduction: Targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for non-small cell lung cancer (NSCLC). However, drug resistance has grown in the last few decades. This study compared the progression time of lung cancer...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Airlangga
2025-01-01
|
| Series: | Jurnal Respirasi |
| Subjects: | |
| Online Access: | https://e-journal.unair.ac.id/JR/article/view/64531 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850077788051079168 |
|---|---|
| author | Elisna Syahruddin Noni Novisari Soeroso Fannie Rizki Ananda Laksmi Wulandari Ana Rima Setijadi Sabrina Ermayanti Suryanti Dwi Pratiwi Andreas Infianto Novita Andayani Sri Melati Munir Avissena Dutha Pratama Ida Ayu Jasminarti Dwi Kusumawardani Haryati Haryati Natalie Duyen Muhammad Alfin Hanif Darren Wan-Teck Lim |
| author_facet | Elisna Syahruddin Noni Novisari Soeroso Fannie Rizki Ananda Laksmi Wulandari Ana Rima Setijadi Sabrina Ermayanti Suryanti Dwi Pratiwi Andreas Infianto Novita Andayani Sri Melati Munir Avissena Dutha Pratama Ida Ayu Jasminarti Dwi Kusumawardani Haryati Haryati Natalie Duyen Muhammad Alfin Hanif Darren Wan-Teck Lim |
| author_sort | Elisna Syahruddin |
| collection | DOAJ |
| description | Introduction: Targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for non-small cell lung cancer (NSCLC). However, drug resistance has grown in the last few decades. This study compared the progression time of lung cancer patients treated with first- and second-generation EGFR-TKI.
Methods: Based on cytology and histological results, this cross-sectional study included 1,008 participants diagnosed with lung adenocarcinoma (LUAD) from 11 Indonesian Respiratory Centers. Every three months, the response to treatment was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria in 1.1. Significant differences in the clinical features of the three TKI treatment groups were identified using logistic regression analysis, the median time to disease progression was estimated using the Kaplan-Meier technique, and independent prognostic factors related to the time to progression (TTP) were assessed using Cox proportional hazards regression.
Results: This study examined 505 patients, the majority of whom were females (50.9%), never smoked (59.8%), diagnosed at an advanced stage (99.2%), and had an Eastern Cooperative Oncology Group (ECOG) scale of 0-1 (83.2%). Approximately 98.1% of patients were treated with afatinib (14.8%), erlotinib (18.6%), and gefitinib (66.1%) due to common mutations. The groups did not differ significantly (p>0.05). The median overall survival (OS) rate was 9 months. The time to LUAD progression in lung cancer was significantly impacted by poor performance (p=0.001).
Conclusion: Epidermal growth factor receptor-tyrosine kinase inhibitor treatment can only prolong the TTP of LUAD by up to 9 months, and the performance scale when receiving the EGFR-TKI significantly affects the prognosis. |
| format | Article |
| id | doaj-art-716d10eaa10b42509052d79b98c8a291 |
| institution | DOAJ |
| issn | 2407-0831 2621-8372 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Universitas Airlangga |
| record_format | Article |
| series | Jurnal Respirasi |
| spelling | doaj-art-716d10eaa10b42509052d79b98c8a2912025-08-20T02:45:43ZengUniversitas AirlanggaJurnal Respirasi2407-08312621-83722025-01-011112230https://doi.org/10.20473/jr.v11-I.1.2025.22-30The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in IndonesiaElisna Syahruddin0https://orcid.org/0000-0002-4383-2240Noni Novisari Soeroso1https://orcid.org/0000-0002-2687-4924Fannie Rizki Ananda2https://orcid.org/0000-0002-5982-2194Laksmi Wulandari3https://orcid.org/0000-0002-5000-0151Ana Rima Setijadi4https://orcid.org/0000-0001-7848-9588Sabrina Ermayanti5https://orcid.org/0000-0002-2956-9845Suryanti Dwi Pratiwi6https://orcid.org/0000-0002-4733-7837Andreas Infianto7https://orcid.org/0009-0001-5800-3322Novita Andayani8https://orcid.org/0009-0006-6032-8296Sri Melati Munir9https://orcid.org/0000-0002-5274-8980Avissena Dutha Pratama10https://orcid.org/0009-0008-8860-9502Ida Ayu Jasminarti Dwi Kusumawardani11https://orcid.org/0000-0002-2716-5222Haryati Haryati12https://orcid.org/0000-0001-8605-9991Natalie Duyen13https://orcid.org/0009-0000-3939-2476Muhammad Alfin Hanif14https://orcid.org/0000-0003-4303-8239Darren Wan-Teck Lim15https://orcid.org/0000-0002-4655-0206Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Lampung, Bandar Lampung, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Syiah Kuala, Aceh, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia.Division of Pulmonary Disease and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Udayana, Denpasar, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia.Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya, Palembang, Indonesia.Department of Pulmonology, Dharmais National Cancer Center Hospital, Jakarta, Indonesia.Division of Medical Oncology, National Cancer Centre Singapore/Duke-NUS Medical School, Singapore.Introduction: Targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for non-small cell lung cancer (NSCLC). However, drug resistance has grown in the last few decades. This study compared the progression time of lung cancer patients treated with first- and second-generation EGFR-TKI. Methods: Based on cytology and histological results, this cross-sectional study included 1,008 participants diagnosed with lung adenocarcinoma (LUAD) from 11 Indonesian Respiratory Centers. Every three months, the response to treatment was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria in 1.1. Significant differences in the clinical features of the three TKI treatment groups were identified using logistic regression analysis, the median time to disease progression was estimated using the Kaplan-Meier technique, and independent prognostic factors related to the time to progression (TTP) were assessed using Cox proportional hazards regression. Results: This study examined 505 patients, the majority of whom were females (50.9%), never smoked (59.8%), diagnosed at an advanced stage (99.2%), and had an Eastern Cooperative Oncology Group (ECOG) scale of 0-1 (83.2%). Approximately 98.1% of patients were treated with afatinib (14.8%), erlotinib (18.6%), and gefitinib (66.1%) due to common mutations. The groups did not differ significantly (p>0.05). The median overall survival (OS) rate was 9 months. The time to LUAD progression in lung cancer was significantly impacted by poor performance (p=0.001). Conclusion: Epidermal growth factor receptor-tyrosine kinase inhibitor treatment can only prolong the TTP of LUAD by up to 9 months, and the performance scale when receiving the EGFR-TKI significantly affects the prognosis.https://e-journal.unair.ac.id/JR/article/view/64531canceregfr-tkilung adenocarcinomaprogression-free survivaltime to progression |
| spellingShingle | Elisna Syahruddin Noni Novisari Soeroso Fannie Rizki Ananda Laksmi Wulandari Ana Rima Setijadi Sabrina Ermayanti Suryanti Dwi Pratiwi Andreas Infianto Novita Andayani Sri Melati Munir Avissena Dutha Pratama Ida Ayu Jasminarti Dwi Kusumawardani Haryati Haryati Natalie Duyen Muhammad Alfin Hanif Darren Wan-Teck Lim The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia Jurnal Respirasi cancer egfr-tki lung adenocarcinoma progression-free survival time to progression |
| title | The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia |
| title_full | The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia |
| title_fullStr | The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia |
| title_full_unstemmed | The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia |
| title_short | The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia |
| title_sort | time to progression in lung adenocarcinoma patients receiving first and second generation egfr tki in indonesia |
| topic | cancer egfr-tki lung adenocarcinoma progression-free survival time to progression |
| url | https://e-journal.unair.ac.id/JR/article/view/64531 |
| work_keys_str_mv | AT elisnasyahruddin thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT noninovisarisoeroso thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT fannierizkiananda thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT laksmiwulandari thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT anarimasetijadi thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT sabrinaermayanti thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT suryantidwipratiwi thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT andreasinfianto thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT novitaandayani thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT srimelatimunir thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT avissenaduthapratama thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT idaayujasminartidwikusumawardani thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT haryatiharyati thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT natalieduyen thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT muhammadalfinhanif thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT darrenwantecklim thetimetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT elisnasyahruddin timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT noninovisarisoeroso timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT fannierizkiananda timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT laksmiwulandari timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT anarimasetijadi timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT sabrinaermayanti timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT suryantidwipratiwi timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT andreasinfianto timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT novitaandayani timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT srimelatimunir timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT avissenaduthapratama timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT idaayujasminartidwikusumawardani timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT haryatiharyati timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT natalieduyen timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT muhammadalfinhanif timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia AT darrenwantecklim timetoprogressioninlungadenocarcinomapatientsreceivingfirstandsecondgenerationegfrtkiinindonesia |